Table 1 Comparison of specific tumour mutations with the IHC or RNA-ISH score of biomarkers known to influence tumorigenesis.
Case no. | KRAS | DDR2 | PMS2 | TP53 | FBXW7 | H3F3C | CDKN2A | MYCN | BARD1 | RAD51C | PTEN | Mutation no. | Desmoplastic reaction (SMA) | T-cell density (CD3) | IDO-1 IHC Score | TGFb mRNA score | c-Met IHC H score | c-Met RNAScope score (ACD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | WT | WT | WT | WT | WT | WT | WT | WT | WT | WT | WT | 0 | 4.8 | 30 | −ve | −ve | 30 | 1.0 |
2 | MT | MT | WT | WT | WT | WT | WT | WT | WT | WT | WT | 2 | 33.1 | 49 | + | −ve | 90 | 3.0 |
3 | WT | WT | MT | WT | WT | WT | WT | WT | WT | WT | WT | 1 | 23.2 | 58 | + | −ve | 140 | 1.6 |
4 | MT | WT | WT | MT | WT | WT | WT | WT | WT | WT | WT | 2 | 37.1 | 38 | ++ | −ve | 50 | 0.8 |
5 | MT | WT | WT | MT | WT | WT | WT | WT | WT | WT | WT | 2 | 27.9 | 26 | −ve | −ve | 140 | 2.5 |
6 | MT | WT | WT | MT | WT | WT | WT | WT | WT | WT | WT | 2 | 39.9 | 26 | + | −ve | 180 | 3.2 |
7 | MT | WT | WT | MT | MT | WT | WT | WT | WT | WT | WT | 3 | 39.6 | 29 | −ve | −ve | 120 | 1.3 |
8 | MT | WT | WT | MT | WT | MT | WT | WT | WT | WT | WT | 3 | 40.4 | 20 | −ve | −ve | 100 | 4.0 |
9 | MT | WT | WT | MT | WT | WT | MT | WT | WT | WT | WT | 3 | 32.3 | 38 | −ve | −ve | 200 | 4.0 |
10 | MT | WT | WT | WT | WT | WT | MT | MT | WT | WT | WT | 3 | 51.0 | 21 | −ve | + | 140 | 2.5 |
11 | MT | WT | WT | MT | WT | WT | MT | WT | WT | WT | WT | 3 | 46.5 | 34 | + | −ve | 220 | 3.2 |
12 | MT | WT | WT | MT | WT | WT | WT | WT | MT | MT | MT | 5 | 63.0 | 30 | +++ | + | 180 | 3.0 |
